Filler-specialized company BioPlus (CEO Hyun-Gyu Jung) announced on the 26th that it had signed a memorandum of understanding (MOU) with urethral catheter specialist UroAll to jointly develop a medical device composed of a urethral catheter with drug-eluting capabilities and a drug called InterBlock to prevent re-stricture of the urethra.

UroAll, located in the Gyeongnam Technovalley in Gimhae, was founded by Professor Myung-Chan Park of the Department of Urology at Inje University Haeundae Paik Hospital and is a company specialized in the development of urological catheters.

The company sells functional 3-way urethral catheters designed to be inserted into the bladder through the urethra to support urination after urological procedures or surgery, as well as to protect the affected area and deliver medication.

Through this agreement, the two companies will develop a medical device consisting of a drug-delivery catheter and InterBlock, an adhesion barrier agent, to prevent and treat urethral stricture and its recurrence.

They expect that the development of this medical device will significantly reduce the pain and recurrence associated with urethral strictures.

A BioPlus representative stated that although InterBlock is currently approved for use in preventing adhesions after spinal surgery, the company plans to expand its indication to the field of urology through this joint research, and will actively seek to broaden InterBlock’s indications in the future.